Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
04:05pm, Thursday, 09'th May 2024
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
04:05pm, Thursday, 09'th May 2024
REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered
Will Gilead Sciences Stock Recover To Its Pre-Inflation Shock Highs Of Around $75?
09:00am, Thursday, 09'th May 2024
Gilead Sciences stock (NASDAQ NASDAQ : GILD) trades at $65 per share, about 11% below the level seen in December 2021. GILD stock was trading at around $62 in early June 2022, just before the Fed star
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
08:30am, Tuesday, 07'th May 2024
FOSTER CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Onc
Bargain Hunting: 7 Stocks Near 52-Week Lows to Buy Before the Bounce Back
12:39pm, Monday, 06'th May 2024
If you really want to maximize your return potential, then acquiring stocks near 52-week lows could present a viable opportunity. Stated simply, it's a way to practice buying low and selling high.
MRNA, GILD: What to Watch in Biotech Stocks
11:53am, Monday, 06'th May 2024
Fiscal discipline is important going forward, notes Hartaj Singh on Moderna (MRNA). He discusses biotech stocks Moderna and Gilead Sciences (GILD).
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar
02:38pm, Wednesday, 01'st May 2024
Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treat
Gilead Sciences to Present at Upcoming Investor Conferences
04:05pm, Tuesday, 30'th Apr 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: BofA Securities Health Ca
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Monday, 29'th Apr 2024
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
3 Dividend Stocks to Buy at a 52-Week Low in April
11:44am, Friday, 26'th Apr 2024
Throughout my journey as an investor, I've learned that some of my most profitable picks stem from purchasing quality businesses when their share prices have been battered. A useful starting point for
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
11:26am, Friday, 26'th Apr 2024
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
08:00am, Friday, 26'th Apr 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the sa
Gilead Sciences, Inc. (GILD) Q1 2024 Earnings Call Transcript
08:26pm, Thursday, 25'th Apr 2024
Gilead Sciences, Inc. (NASDAQ:GILD ) Q1 2024 Earnings Conference Call April 25, 2024 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say
07:01pm, Thursday, 25'th Apr 2024
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street e
Gilead Sciences (GILD) Reports Q1 Loss, Tops Revenue Estimates
06:16pm, Thursday, 25'th Apr 2024
Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1.37 per share a year ago.
